Epstein - Barr virus
Introduction
Epstein - Barr virus can best be categorized as a collective human pathogen infecting the majority in global context (Hal, 2011). It is a virus that originates from the Herpes family which incorporates Herpes simplex virus as well as cytomegalovirus thus becoming one of the common virus amongst human beings most individuals are initially infected by EBV which in most cases is asymptomatic but mostly result in mononucleosis infection (Hal, 2011). Epstein - Barr virus can thus result in the infection which is universally referred to as glandular fever. The infectious mononucleosis is a result of an individual being exposed to the Epstein- Barr virus during or post the adolescence period. The virus is a global occurrence and most individuals are bound to be infected with this virus in a certain period in life. Infants, in particular, becomes EBV vulnerable as soon as the disappearance of maternal antibody guards occurs which is given at birth. With the extent of this contamination midst, most children the virus does not frequently result in indications or they are unclear from all another brief, unimportant infantile illnesses. In America as well as in the developed nations most individuals are infected with Epstein - Barr virus during their childhood lives (Hal, 2011). When Epstein - Barr infection occurs either during the young or the adulthood stage this causes mononucleosis infection which accounts to 35 up to 50 percent of the period (Sulika et al, 2014).
More than 90 percent of the global adult populace is infected by Epstein - Barr virus thus carrying the virus throughout their lives (Sulika et al, 2014). It is the prime infection that results in asymptomatic seroconversion which might be the variable mononucleosis infection harshness. People with considerable cellular immunodeficiency are most likely to acquire lymph-proliferative malignancies disorders despite the fact that most of these carriers remain free from illnesses in their lifetime (Hal, 2011). EBV usually infects the inexperienced B-cells that are situated in the lymphoid body tissues thus changing them into proliferating lymphoblast that is particularly activated. In occasions, EBV might infect other kinds of cells particularly Oropharyngeal Epithelial Cells. The prime EBV contagion normally stimulates an aggressive cytotoxic T-cell reply which is essential in lymph proliferation limitation particularly of the disease-ridden B cells (Sulika et al, 2014). Severe mononucleosis infection presents an enormous preponderance of the mononuclear cells amongst the mingling leukocytes.
EBV infection leads to an illnesses range with the resistant host reply playing a chief part in the modelling of the medical entrances. Infectious mononucleosis can be described as the EBV Infection model that is frequently characterized by semantic problems connected to tiredness, fever, illness, sore-throat, prevalent and cervical lymphadenopathy besides the hepatosplenomegaly (Acton, 2012). The condition is most commonly a non-threatening, self-controlled infection in the healthy individuals. Infectious mononucleosis can best be defined as the illness that results from EBV primary infection despite that other agents causes similar infectious mononucleosis disorders that are medically similar to the related EBV illness. The violent nonmalignant EB related proliferations like hemophagocytic syndrome and PTLS–Post-transplant Lymph proliferative syndrome occur in individuals with compromised immune system. In addition, EBV usually contributes to human beings distortions that include leiomyosarcoma, Burkitt Lymphoma as well as Hodgkin illness (Hal, 2011).
EBV- History of Recognition and Discovery
EBV’s discovery history as the primary infectious mononucleosis cause started with the initial medical description related to the illness known as Subacute Febrile which was conducted in 1885 by Filatov and the glandular fever description that was done in the year 1889 by Pfeifer (Ahmed, Philip, Tariq, & Khan, 2014). In the year 1920, Evans and Sprunt offered a detailed description of the atypical lymphocytes findings and ultimately created the term infectious mononucleosis as the description of the ailment. EBV discovery was, in addition, the first identification of the human beings tumor based virus. In the year 1964, Barr, Achong, and Epstein were able to discover the presence of some herpes virus in the jaw’s sarcomas tissues that had been gathered from children living in the African region (Almohmeed, Avenell, Aucott, & Vickers, 2013). This led to the linking of the virus in the year 1968 with the new discovery occurrence which was of the infectious mononucleosis by Werner Henle and Gertrude together with Niederman who confirmed the existing epidemiologic association (Hal, 2011). EBV thus become the first most virus to be associated with human beings cancer and this led to it becoming the first human tumor infection in discovery and recognition.
Epidemiology
EBV is categorized to be the y-herpes virus which possesses a DNA genome that is double stranded of the 184-kb measurement pairs which encode close to a hundred proteins. The two differentiated types which are type A and B which are additionally known as type 1 and 2 shares about 70 up to 85 percent homology sequence. EBV-1 is the more common in the global context when equated to EBV -2 which is in most cases established in the African region. The prime EBV cellular target is known as lymphocyte-B (Hal, 2011). The EBV-1 induces the growth of B-cells transformation in a more efficient manner than the EBV -2. However, both infection types’ leads to lifelong infection without any identified kind-specific distinction in reference to the illness. The multiple, as well as the dual illness infection with the two EBV types, so far have been identified and documented in individuals who possess a compromised immune.
Given that EBV establishes lifelong illness infection, EBV infection usually increases with age increase. More than 95 percent of the global adult’s populace is infected chronically and seropositive. There is no any kind of symptoms that are established from the dormant persisting infection that comes after the initial infection (Hal, 2011). EBV is usually transmitted mainly by oral saliva contact which is most common in saliva exchange amongst the young individuals in direct association or in children while handling toys or during kissing amongst adolescents which accounts to the infectious mononucleosis being highly regarded as the kissing illness. EBV is out built in oral emissions constantly and the highest concentration for over a period of six months that follows an acute infection as well as intermittently at lower life concentration. There the transmission risk is usually higher from the recent scenarios with several transmission risks from any individuals that have ever acquired the infection. At any given period as many individuals as amid 20 and 30 percent of the healthy adults who have developed the EBV infection, even in the previous years, shed EBV infection in lower oral emissions concentrations (Aly Loutfy et al, 2017). The immunosuppression plays part in the reactivation of EBV latent and the EBV-infected portion where individuals who are suppressed in regard to immune emit the viral in oral nature thus increasing the prevalence to about 60 up to 90 percent. EBV is established both in the female as well as male emissions and can be exchanged during the sexual engagement (Andersson & Andersson, 1993).
Infectious mononucleosis epidemiology of medical principle is usually connected to the acquisition age of the EBV contamination. Despite the fact that infectious mononucleosis may develop and recognized in individuals of all ages it rare cases it recognized in children below four years since most infections are termed as asymptomatic. In addition, the infection is additionally rare amongst adults who are over 30 up to 40 years when most individuals have already been infected with the virus (Hal, 2011). In the developing nations and amongst the populace that is socio-economically challenged in the developed countries the EBV transmission occurs almost collectively in the early childhood and infancy stages. In the central region of Africa, almost all the children are infected with the virus by the time they turn three years which leads to the development of asymptomatic infection and in other times minor illness that cannot be differentiated from most of the other childhood infections as they hold almost the same symptoms. Therefore, infectious mononucleosis being an illness is technically not well understood particularly in the underdeveloped regions in the global (Apostolou et al, 2017).
Contrary in the industrialized nations and amongst affluent persons, infection in the childhood period normally takes place in less frequency, in particular, because of the high hygiene measures with a projection of about a third EBV transmissions happening during the adolescence period as well as amongst the young populace. Mainly, EBV development among the adolescent populace as well as adults is associated with a number of symptoms for above an approximation of 50 percent amid the infected persons (Assadian et al, 2017). The infections normally show a characteristic infectious mononucleosis fatigue threesome, lymphadenopathy as well as pharyngitis. The cases of infectious mononucleosis particularly in America is projected to be amid 20 up to 70percent in every a hundred thousand individuals every year among the youth populace and the incidences normally rise to up to close to a hundred persons in every a hundred thousand individuals (Hal, 2011).
Pathogenesis
Following the transmission that occurs through the oral cavity, primarily EBV affects the epithelial oral cells which occur with the severe duplication, virions proclamation, and cell lysis that usually spread to the contiguous structures that incorporate the salivary storage. The basic spread within the lymphoid and oral epithelial cells acts as the major grounds of pharyngitis symptoms (Balandraud et al, 2017). Viremia normally follows, with the prime cellular EBV target, the whole lymphoreticular system that incorporates the spleen and the human liver as well as the Lymphocytes-B. It is worth noting that the lymphocytes that are hosted in the peripheral blood which is associated with infectious mononucleosis are the well-developed CD8-plus Lymphocytes-T which contains both the cytotoxic and suppressor responsiveness. All these being the atypical lymphocytes in usual are activated anti-genetically being a major part of the EBV responsive immune that is affected by Lymphocytes –B. The complete rise of lymphocytes CD8 plus normally leads to reversal transient of the 2 to 1 ration (Banko et al, 2016). The pattern, however, differs from the CD4 plus/CD8 plus ration observed in the immune deficiency in humans with the HIV viral infection by the complete Lymphocytes concentration.
The immune response host normally lowers the EBV burden circulation in the human blood peripheral to lesser than a single copy of 10 five squared B-lymphocytes circulation which is equal to low than 10 DNA ug copies in the entire individual’s blood (Bienemann et al , 2015). In the compromised individual’s immune, the encumbrance of EBV tends to be high and usually above 4,000 DNA ug copies. In addition, EBV normally affects the lymphocytes-T that is equated with the infection caused by EBV on the B-lymphocytes. EBV is normally recognized for infecting the epithelial body cells specifically of the cervix uterine despite that there are no local symptoms that have been defined or recognized as sexual contact transmission. However, it has been demonstrated additionally that EBV also affects the smooth muscle’s human cells found in the leiomyosarcomas that usually rise in individuals with compromised immune system. Following the main infection, similarly to other herpesviruses EBV usually establishes a persisting dormant contamination for the hosting individual’s life (Bjørnevik et al, 2017). The dormant EBV infection in usual cases basically ports locally within the epithelial oropharyngeal cells as well as within the B-lymphocytes memory in a systematic manner. Dormant EBV normally generates low viral proteins particularly the nuclear EBV antigens (EBNAs). Specifically, these proteins are involved in maintaining the infectious virus during the dormant period while the multiple spherical copies which are also referred as episomes that occur in the nuclear that are separated from the chromosome cells. EBV perseveres because of the severe replication of episomes with the division of cells thus migrating to the two daughter cells in the mitosis process. In contra-difference, in Burkitt Lymphoma cases, EBV integrates into the chromosome cells with the translocation of reciprocal (Bowden et al 2012).
According to Brocqueville, et al (2013), For some reasons that remains unclear, some dormant affected B-lymphocytes gets into the severe replicative or rather a cycle that starts with early production of antigens (EAs) which proceeds to the viral replication of DNA that is accompanied by the structural production of glycoproteins that includes the Viral Capsid Antigens (VCAs) manufacturing and concludes in the death cells with mature virions release that are usually released via secretions. Then they infect other B-lymphocytes in a systematic nature. The reactivation is specifically asymptotic one (Busch, 2014).
Clinical Aspects
Infectious mononucleosis incubation period, particularly in adults as well as adolescents, is about 30 up to 50 days which might be lower in children. Mainly EBV infection in the younger populace in this case children are categorized as asymptomatic. This means that the symptoms it generates fail to differentiate EBV as the prime cause of most of the febrile infections which normally happen during the childhood stage (Camargo et al, 2016). Amongst adults as well as adolescents the infectious mononucleosis medical syndrome is a characteristic one. The illness’s commencement is insidious in usual which occurs in over one up two weeks with systematic complaints that are not specified related to fatigue, sickness and a low degree fever that is accompanied by lymphadenopathy painful or untender throat and in most cases vomiting, headache, stomach ache as well as myalgia. Complaints related to a fever and severe sore throat increases progressively thus necessitating medical treatment. In most instances, the bestowing complaints that are highly recorded are tenderness and upper quarter abdominal uneasiness because of the rapid splenomegaly growth (Chung-Chun, et al, 2017).
Medical physical examination mainly reveals pharyngitis which is in usual accompanied by average tonsillar expansion and in occasions with exudates which is complex to differentiate from the pharyngitis streptococcal. Petechial is common at the soft and hard palate connection. The effects normally affect reticuloendothelial system which is affirmed by a simplification of about 90 percent lymphadenopathy cases, 50 percent splenomegaly while the hepatomegaly cases account for 10 percent of all the recorded cases. Both in the posterior and anterior cervical and submandibular lymph nodes lymphadenopathy is rare (Crawford, Rickinson & Johannessen, 2014). Conventionally, epitrochlear lymphadenopathy is a prime infectious mononucleosis demonstration given that the findings are an unusual section of the comprehensive lymphadenopathy (Dalamaga et al, 2013). Despite the fact that increased expansion or enlargement is not often the presence of a tw0 up to three cm Splenomegaly is usual.
In a projection of about three up to 15 percent of the infected patient's rashes normally happen and in typical are Maculopapular. Close to or above 80 percent of these patients who acquire the infectious mononucleosis treatment with ampicillin normally experiences rashes related to this treatment (Dekate & Chetty, 2016). However, the experience happens in less frequency with the use of amoxicillin treatment as well as other beta-lactam family antibiotics. The copper colored pruritic outbreak is most potent immune mediated and thus it does not necessitate any particular treatment option except for the suspension of antibiotic use post which the outbreak usually resolves. EBV is additionally linked to Gianotti-Crosti condition (Dunmire et al, 2014). This is can best be described as the symmetric rash that holds the appearance of dermatitis atopic. In addition, there are usually a number of numerous erythematous papules that occurs particularly on the boundaries, cheeks as well as buttocks and might even grow into plaques and persistence rashes for about 15 up to 50 days (Dong Won et al, 2017).
The Non-nonmalleable EBV related proliferative illness usually occurs in individuals with a compromised immune such as for the individuals who are infected with HIV as well as transplant recipients for major organs such as kidneys (Eagle, 2011). Pneumonitis Interstitial Lymphoid in normal cases happens in young children who are characterized by HIV/AIDS which results in mild respiratory related illnesses. In addition, Oral Leukoplakia that is covered by hair develops in adults with the AIDS virus which is usually characterized by white covers on the tongue’s lateral boundaries (Foster & Vitale, 2013). The Operation of the mentioned lesions determines high and extreme EBV duplication levels (Gantuz et al, 2017).
Diagnosis
Typical medical symptoms presence which is along with uncharacteristic lymphocytosis in the human peripheral blood is a suggestion of medical infectious mononucleosis. The diagnosis is required to be confirmed by the utilization of serologic examination for either specific EBV or heterophile antibodies (Gieß, 2017). In reference to infectious mononucleosis, the white blood cells count can either be normal or a revelation of the existence of slight leukocytosis with the account of about 2/3rd of all the white blood cells. The uncharacteristic lymphocytes normally account for about 20 up to 40 percent of all the white cells (Goldstein et al, 2017). Despite that, the uncharacteristic lymphocytes develop with the acquisition of cytomegalovirus infection, viral hepatitis, typhoid, malaria, and tuberculosis as well as some reactions that are associated with a number of drugs. Slight thrombocytopenia develops in about 25 up to 50 percent of the infected populace and s not often linked to these symptoms (Gumbo 2014). On the other hand, serious thrombocytopenia is rare occurrence. The slight hepatic transaminases increase is observed in a projection of 50 percent of those cases that are not associated with any complications but the involvement of the liver is indistinguishable with no jaundice.
Heterophile Antibody Examination
Heterophile antibodies can best be defined by their clump cells features from the classes that are different from the ones of the serum source. The fleeting heterophile that are observed within infectious mononucleosis which is referred to as Paul-Bunnell (Hagan et al, 2017). The heterophile antibody examination responses that occurs while using sheep’s red cells are in most cases positive for a number of months post the prime infectious mononucleosis while the examination of the horse can sustain positivity for over two years. The most utilized approach in the determination of heterophile is a qualitative erythrocytes examination. The tests usually determine the existence of these antibodies in close to 90 percent of the EBV linked infections that develop amongst adolescents and adults but in just about 50 percent of these cases are observed amongst younger children below 4 years because practically the children normally grow titers that are low (Hayat, 2012). Based on this rationale the heterophile examination is not suggested for the diagnostic assessment for the presence of infectious mononucleosis amongst children who are below the age of 4 years.
Roughly 5 up to 10 percent of the clear infectious mononucleosis cases are not the result of EBV and fails to constantly hold a heterophile assessment response. The incorrect desirable rate is usually lesser than 10 percent that results from mistaken clarification (Höcker, 2013). If the heterophile examination leads to negative findings with the EBV infection uncertainty it is usually recommended that a specific EBV antibody examination is conducted for clarification and establishment of the most appropriate treatment approach (Hoffman, n.d.).
EBV Antibody Examination
Specific antibody examinations are best in confirming the existence of EBV infection. The examinations are usually of essence in the diagnosis of severe EBV infection, particularly with a resulting negative heterophile examination result. The tests, in addition, are helpful in the confirmation of previous infections thus determining the potential of further contamination in reference to EBV contamination. There are several differentiated EBV antigens systems that utilize differentiated EBV genes that are utilized in the diagnosis objectives. The EA, Nuclear EBNA, as well as VCA, tends to be the most helpful tools in accomplishing the diagnostic goals. VCA examinations are sufficient on confirming EBV infections on its own (Hosseini-Moghaddam et al, 2016). EA antibodies are usually determinable in 80 percent of the affected populace in the severe infectious mononucleosis stage for a few months post the primary infection. On the other hand, EBNA antibodies grow relatively later post the EBV infection and appear progressively in the period of three to four months after the acquisition thus remaining at consistent detectability. The EBNA antibodies presence absence with other specific EBV antibodies being determinable is an implication of a recent virus infection with just a few months or rather weeks. However, EBNA antibodies presence means that the infection occurs in about three up to four months in the previous which could be within any period in the individual’s life (Jons, Sundström, & Andersen, 2015).
Differential Diagnosis
About 5 to 10 percent of the most uncomplicated infectious mononucleosis cases are generated zero EBV (Kato, Imai, Ochiai & Ogata, 2013). The infections that are similar to infectious mononucleosis are a result of prime infects by differing pathogens such as viral hepatitis, HIV and rubella virus. In addition, cytomegalovirus is an often cause of illnesses similar to infectious mononucleosis, particularly in adults. Streptococcal pharyngitis is bound to result in a sore throat which is hard to differentiate from that occurs with infectious mononucleosis. Given that the carriage rate is about 5 percent the failure to acquire health improvement after streptococcal pharyngitis with two to three days is a suggestion of the presence of infectious mononucleosis (Kraus 2017).
In the medical practice, the source of most EBV negative cases of diseases that are similar to infectious mononucleosis is not yet understood based on the confirmatory examination expenditures as well as the absence of medical imperative in establishing the self-controlled illness cause (Kuniholm 2013). Patients having the medical results of infectious mononucleosis in the high presence of the number of white cells that are combined with minimal to serious thrombocytopenia are a suggestion of leukemia which might recommit bone marrow test and hematologic session in without the diagnosis.
Treatment/Management
Observation over time period along with symptomatic treatment is usually the main management option for EBV infection. A sore throat is mainly managed with the utilization of no steroidal anti- provocative medications, acetaminophen as well as the gargling of salt water in addition to several other symptomatic medications. With the incapacitating fatigue, one is required to rest more (Kwok, Chan, Chan, & Chiang, 2015). In addition, the continuance participation in normal activities that leads to normal activities resumption is a recommendation. It is normal to offer advice against the participation of sports that encourages more body contact in the first two to three weeks of the ailment with the presence of splenomegaly in the minimization of splenic rupture risk. The medical success of participation in therapy is low thus high acyclovir doses are a necessity with or with no company of corticosteroids (Li et al, 2017).
Short duration corticosteroids courses for less than two weeks are shown in a few specified infection complication related to infectious mononucleosis (Matsubara, et al, 2003). There is no kind of controlled information demonstrating the indications efficacy as well as their utilization in the off-labels. In general, the accepted indications usually indicates upper airway emerging impediment, meningitis, appropriations as well as thrombocytopenia that convoluted mainly by the presence of bleeding conditions (William, 2015). One of the suggested routines is referred as prednisone one for every day with the highest accounting to just 60mg every day that is accompanied by a tapering routine of more than 7 more days (Thompson and Kurzrock, 2004). In the perspective of the probable and the unestablished immunosuppression hazards for the infectious virus can be associated with oncogenic problems then corticosteroids are not to be utilized in routine nature.
Complications
There is an undying need in the development of EBV infection virus based on the associated risk of related infections, its increase in the global context and persistence (Visser et al, 2014). Despite the fact that some common complications amongst the healthy individuals are yet to be established the most severe complication historically is hemorrhage which is associated with trauma. In addition, the occurrence of ruptures has been reported mainly within the second week of the ailment which accounts for less than 0.5 percent of the adults (Scheld et al, 2014). The general rate amidst children is not established but is probably lower.
Tonsillar expansion may lead to the obstruction of the upper part airway. In addition, most uncommon as well as rare neurologic conditions are in particular reported to having a direct association with the infectious mononucleosis (Robertson, 2010). In close to 50 percent of this cases, head ache is common but severe complication like seizure are amongst less than 1 percent of the populace. Myocarditis and pneumonia can also occur which both resolves within three up to four weeks. Severe infectious mononucleosis is said to be rare amid adults but may occur based on the unmanaged lymph proliferative response. The treatment with the use of episode that is effective in the reduction of monocyte as well as macrophage operations along with corticosteroids can be an effective option (Simpson, Taylor & Van der Mei, 2015).
Prognosis
For the complete recovery’s prognosis from the IM is efficient as the symptoms normally last for about two up to four weeks that are followed by a progressive but rather stable recovery. Some patients, however, experience long run symptoms as well as signs that in other times uncomfortable fatigue and illness that may persist for a number of weeks for up to about 6 months (Ting-bo et al, 2017). There is no direct or justifiable evidence that connects EBV infection to the prolonged fatigue complication. There are some secondary infections that possess differing EBV kinds which have been recorded in individuals with complicated immune but there are no symptoms or secondary attacks resulting from infectious mononucleosis that is a source of EBV in record as per today (Torii et al, 2017).
Conclusion
More than 90 percent of the global adult populace is infected by Epstein - Barr virus thus carrying the virus throughout their lives. EBV infection diagnosis is usually confirmed best through the use of serologic examination. It is demonstrated by expert’s studies that infectious mononucleosis management is of prime support on the path to recovery. Based on the most recent statistics it is apparent that the most beneficial intervention is the development of EBV vaccines in lower the risks of illnesses associated with EBV infection.
References
Acton, Q. A. (2012). Epstein-Barr virus infections: Advances in research and treatment: ScholarlyPaper.
Ahmed, W., Philip, P. S., Tariq, S., & Khan, G. (2014). Epstein-Barr Virus-Encoded Small RNAs (EBERs) Are Present in Fractions Related to Exosomes Released by EBV-Transformed Cells. Plos ONE, 9(6), 1-8. doi:10.1371/journal.pone.0099163
Almohmeed, Y. H., Avenell, A., Aucott, L., & Vickers, M. A. (2013). Systematic Review and Meta-Analysis of the Sero-Epidemiological Association between Epstein Barr Virus and Multiple Sclerosis. Plos ONE, 8(4), 1-15. doi:10.1371/journal.pone.0061110
Aly Loutfy, S., Abo-Shadi, M. A., Fawzy, M., El-Wakil, M., Metwally, S. A., Moneer, M. M., & ... Elgebaly, A. (2017). Epstein-Barr virus and cytomegalovirus infections and their clinical relevance in Egyptian leukemic pediatric patients. Virology Journal, 141-11. Doi: 10.1186/s12985-017-0715-7
Aly Loutfy, S., Abo-Shadi, M. A., Fawzy, M., El-Wakil, M., Metwally, S. A., Moneer, M. M., & ... Elgebaly, A. (2017). Epstein-Barr virus and cytomegalovirus infections and their clinical relevance in Egyptian leukemic pediatric patients. Virology Journal, 141-11. Doi: 10.1186/s12985-017-0715-7
Andersson, J., & Andersson, U. (1993). Characterization of cytokine production in infectious mononucleosis studied at a single-cell level in tonsil and peripheral blood. Clinical & Experimental Immunology, 92(1), 7-13.
Apostolou, F., Gazi, I., Lagos, K., Tellis, C., Tselepis, A., Liberopoulos, E., & Elisaf, M. (2010). Acute infection with Epstein–Barr virus is associated with atherogenic lipid changes. Atherosclerosis (00219150), 212(2), 607-613. doi:10.1016/j.atherosclerosis.2010.06.006
Assadian, F., Kamel, W., Laurell, G., Svensson, C., Punga, T., & Akusjärvi, G. (2017). Expression profile of Epstein-Barr virus and human adenovirus small RNAs in tonsillar B and T lymphocytes. Plos ONE, 12(5), 1-21. doi:10.1371/journal.pone.0177275
Balandraud, N., Texier, G., Massy, E., Muis-Pistor, O., Martin, M., Auger, I., & ... Roudier, J. (2017). Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study. Plos ONE, 12(2), 1-13. doi:10.1371/journal.pone.0171623
Banko, A. V., Lazarevic, I. B., Folic, M. M., Djukic, V. B., Cirkovic, A. M., Karalic, D. Z., & ... Jovanovic, T. P. (2016). Characterization of the Variability of Epstein - Barr virus Genes in Nasopharyngeal Biopsies: Potential Predictors for Carcinoma Progression. Plos ONE, 11(4), 1-16. doi:10.1371/journal.pone.0153498
Bienemann, K., Borkhardt, A., Klapper, W., & Oschlies, I. (2015). High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency. Histopathology, 67(5), 607-616. doi:10.1111/his.12677
Bjørnevik, K., Riise, T., Bostrom, I., Casetta, I., Cortese, M., Granieri, E., & ... Myhr, K. (2017). Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. Multiple Sclerosis Journal, 23(7), 1018-1024. Doi: 10.1177/1352458516671028
Bowden, R. A., Ljungman, P., & Snydman, D. R. (2012). Transplant infections.n.a
Brocqueville, G., Ndour, P. A., Ouk, T., Le Goff, A., De Witte, C., Mougel, A., & ... Adriaenssens, E. (2013). LMP1-Induced Cell Death May Contribute to the Emergency of Its Oncogenic Property. Plos ONE, 8(4), 1-10. doi:10.1371/journal.pone.0060743
Busch, D., Hilswicht, S., Schöb, D. S., Von Trotha, K. T., Junge, K., Gassler, N., & ... Binnebösel, M. (2014). Fulminant Epstein-Barr virus - infectious mononucleosis in an adult with liver failure, splenic rupture, and spontaneous esophageal bleeding with ensuing esophageal necrosis: a case report. Journal of Medical Case Reports, 8(1), 3-12. Doi: 10.1186/1752-1947-8-3
Camargo, M. C., Kim, K., Matsuo, K., Torres, J., Liao, L. M., Morgan, D. R., & ... Rabkin, C. S. (2016). Anti-Helicobacter pylori Antibody Profiles in Epstein-Barr virus (EBV)-Positive and EBV-Negative Gastric Cancer. Helicobacter, 21(2), 153-157. doi:10.1111/hel.12249
Chung-Chun, W., Chih-Yeu, F., Yu-Jhen, C., Hui-Yu, H., Sheng-Ping, C., Sheng-Yen, H., & ... Jen-Yang, C. (2017). Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin. Journal of Biomedical Science, 241-13. Doi: 10.1186/s12929-016-0313-9
Crawford, D. H., Rickinson, A., & Johannessen, I. (2014). Cancer virus: The story of Epstein-Barr virus. Oxford: Oxford University Press.
Dalamaga, M., Karmaniolas, K., Chavelas, C., Liatis, S., Matekovits, H., & Migdalis, I. (2003). Fusobacterium necrophorum septicemia following Epstein-Barr virus infectious mononucleosis. Anaerobe, 9(6), 285. doi:10.1016/j.anaerobe.2003.08.002
Dekate, J., & Chetty, R. (2016). Epstein - Barr virus--Associated Smooth Muscle Tumor. Archives of Pathology & Laboratory Medicine, 140(7), 718-722. doi:10.5858/arpa.2015-0120-RS
Dong Won, B., Byung Woog, K., Soyoon, H., Jong Gwang, K., An Na, S., Han Ik, B., & ... Wansik, Y. (2017). Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. Chonnam Medical Journal, 53(2), 140-146. doi:10.4068/cmj.2017.53.2.140
Dowd, J. B., Palermo, T., Brite, J., McDade, T. W., & Aiello, A. (2013). Seroprevalence of Epstein - Barr virus Infection in U.S. Children Ages 6-19, 2003-2010. Plos ONE, 8(5), 1-7. doi:10.1371/journal.pone.0064921
Dreyfus, D. H. (2017). Genetics and Molecular Biology of Epstein-Barr Virus-Encoded BART MicroRNA: A Paradigm for Viral Modulation of Host Immune Response Genes and Genome Stability. Journal of Immunology Research, 1-8. doi:10.1155/2017/4758539
Dunmire, S. K., Grimm, J. M., Schmeling, D. O., Jr.Balfour, H. H., & Hogquist, K. A. (2015). The Incubation Period of Primary Epstein - Barr virus Infection: Viral Dynamics and Immunologic Events. Plos Pathogens, 11(12), 1-18. doi:10.1371/journal.ppat.1005286
Dunmire, S. K., Odumade, O. A., Porter, J. L., Reyes-Genere, J., Schmeling, D. O., Bilgic, H., & ... Hogquist, K. A. (2014). Primary EBV Infection Induces an Expression Profile Distinct from Other Viruses but Similar to Hemophagocytic Syndromes. Plos ONE, 9(1), 1-10. doi:10.1371/journal.pone.0085422
Eagle, S. (2011). Diseases in a Flash! An interactive, flash-card approach. Philadelphia: F.A. Davis Company.
Foster, C. S., & Vitale, A. T. (2013). Diagnosis and treatment of uveitis. New Delhi: Jaypee Brothers Medical.
Gantuz, M., Lorenzetti, M. A., Chabay, P. A., & Preciado, M. V. (2017). A novel recombinant variant of latent membrane protein 1 from Epstein Barr virus in Argentina denotes phylogeographical association. Plos ONE, 12(3), 1-20. doi:10.1371/journal.pone.0174221
Gieß, R. M., Pfuhl, C., Behrens, J. R., Rasche, L., Freitag, E., Khalighy, N., & ... Ruprecht, K. (2017). Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. Plos ONE, 12(4), 1-14. doi:10.1371/journal.pone.0175279
Goldstein, B. L., Chibnik, L. B., Karlson, E. W., & Costenbader, K. H. (2012). Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women. Autoimmunity, 45(2), 161-168. doi:10.3109/08916934.201
Gumbo, H., Chasekwa, B., Church, J. A., Ntozini, R., Mutasa, K., Humphrey, J. H., & Prendergast, A. J. (2014). Congenital and Postnatal CMV and EBV Acquisition in HIV-Infected Zimbabwean Infants. Plos ONE, 9(12), 1-16. doi:10.1371/journal.pone.0114870
Hagan, K. A., Munger, K. L., Ascherio, A., & Grodstein, F. (2016). Epidemiology of Major Neurodegenerative Diseases in Women: Contribution of the Nurses' Health Study. American Journal of Public Health, 106(9), 1650-1655.
Hal B. Jenson. (2011).Epstein-Barr Virus. Gateway journal Retrieved from http://pedsinreview.aappublications.org/content/32/9/375
Hayat, M. A. (2012). Stem cells and cancer stem cells: Volume 5. Dordrecht: Springer.
Höcker, B., Fickenscher, H., Delecluse, H., Böhm, S., Küsters, U., Schnitzler, P., & ... Tönshoff, B. (2013). Epidemiology and Morbidity of Epstein - Barr virus Infection in Pediatric Renal Transplant Recipients: A Multicenter, Prospective Study. Clinical Infectious Diseases, 56(1), 84-92.
Hoffman, R. (n.d.). Hematology: Basic principles and practice. New York: Elsevier Churchill Livingstone.
Hosseini-Moghaddam, S., Alhomayeed, B., Soliman, N., Weir, M., & House, A. (2016). Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study. Transplant Infectious Disease, 18(3), 423-430. doi:10.1111/tid.12533
Jons, D., Sundström, P., & Andersen, O. (2015). Targeting Epstein- Barr virus infection as an intervention against multiple sclerosis. Acta Neurologica Scandinavica, 131(2), 69-79. doi:10.1111/ane.12294
Kato, A., Imai, K., Ochiai, K., & Ogata, Y. (2013). Higher Prevalence of Epstein–Barr Virus DNA in Deeper Periodontal Pockets of Chronic Periodontitis in Japanese Patients. Plos ONE, 8(8), 1-5. doi:10.1371/journal.pone.0071990
Kliegman, R., & Nelson, W. E. (2011). Nelson textbook of pediatrics. Philadelphia, PA: Elsevier/Saunders.
Kraus, R. J., Yu, X., Cordes, B. A., Sathiamoorthi, S., Iempridee, T., Nawandar, D. M., & ... Mertz, J. E. (2017). Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus’s natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter. Plos Pathogens, 13(6), 1-34. doi:10.1371/journal.ppat.1006404
Kuniholm, M. H., Parrinello, C. M., Anastos, K., Augenbraun, M., Plankey, M., Nowicki, M., & ... Kaplan, R. C. (2013). Hepatitis C Viremia Is Associated with Cytomegalovirus IgG Antibody Levels in HIV-Infected Women. Plos ONE, 8(4), 1-7. doi:10.1371/journal.pone.0061973
Kwok, H., Chan, K. W., Chan, K. H., & Chiang, A. S. (2015). Distribution, Persistence and Interchange of Epstein - Barr virus Strains among PBMC, Plasma and Saliva of Primary Infection Subjects. Plos ONE, 10(3), 1-18. doi:10.1371/journal.pone.01207
Lande, M. B., Mowry, J. A., Houghton, D. C., White, C. R., & Borzy, M. S. (1998). Immune complex disease associated with Epstein-Barr virus infectious mononucleosis. Pediatric Nephrology, 12(8), 651-653.
Levine, P. H., Ablashi, D. V., Pearson, G. R., & Kottaridis, S. D. (1985). Epstein - Barr virus and Associated Diseases: Proceedings of the First International Symposium on Epstein-Barr Virus-Associated Malignant Diseases (Loutraki, Greece-September 24-28, 1984). Boston, MA: Springer US.
Li, X., Bhaduri-McIntosh, S., & Burton, E. M. (2017). Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells. Plos Pathogens, 13(3), 1-18. doi:10.1371/journal.ppat.1006249
Liwei, G., Zhengde, X., & Kunling, S. (2014). Epstein - Barr virus Associated Infectious Diseases in Children. American Journal of Biomedical Sciences, 6(4), 217-228. Doi: 10.5099/aj140400217
Mandage, R., Telford, M., Rodríguez, J. A., Farré, X., Layouni, H., Marigorta, U. M., & ... Santpere, G. (2017). Genetic factors affecting EBV copy number in lymphoblastoid cell lines derived from the 1000 Genome Project samples. Plos ONE, 12(6), 1-19. doi:10.1371/journal.pone.0179446
Mao, Y., Lu, M. P., Lin, H., Zhang, D. W., Liu, Y., Li, Q. D., & ... Zhu, J. (2013). Prognostic Significance of EBV Latent Membrane Protein 1 Expression in Lymphomas: Evidence from 15 Studies. Plos ONE, 8(4), 1-9. doi:10.1371/journal.pone.0060313
Martina Vockerodt, Lee-Fah Yap,Claire Shannon-Lowe, Helen Curley, Wenbin Wei,Katerina Vrzalikova and Paul G Murray. (2015). The Epstein–Barr virus and the pathogenesis of lymphoma. Journal of Pathology, 312–322. DOI: 10.1002/path.4459
MATSUBARA, T., ANWAR, R., FUJIWARA, M., ICHIYAMA, T., & FURUKAWA, S. (2003). CTLA-4 (CD152) expression in peripheral blood T cells in Kawasaki disease. Clinical & Experimental Immunology, 132(1), 169-173. doi:10.1046/j.1365-2249.2003.02109.x
Matthew P. Thompson and Razelle Kurzrock. (2004). Epstein - Barr virus and Cancer. Clinical cancer research Vol. 10, 803-821.
Moretti, M., Lava, S. A., Zgraggen, L., Simonetti, G. D., Kottanattu, L., Bianchetti, M. G., & Milani, G. P. (2017). Acute kidney injury in symptomatic primary Epstein-Barr virus infectious mononucleosis: Systematic review. Journal of Clinical Virology, 9112-17. doi:10.1016/j.jcv.2017.03.016
Munger, K., Levin, L., O’Reilly, E., Falk, K., & Ascherio, A. (2011). Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Multiple Sclerosis Journal, 17(10), 1185-1193. Doi: 10.1177/1352458511408991
Münz, C. (2015). Epstein Barr virus: One herpes virus: many diseases. Springer.
Münz, C. (2015). Epstein Barr virus: Volume 2. Springer.
Nordstrom [1], M., Hardell[1], L., Lindstrom[2], G., Wingfors[2], H., Hardell[2], K., & Linde[3], A. (2000). Concentrations of Organochlorines Related to Titers to Epstein - Barr virus Early Antigen IgG as Risk Factors for Hairy Cell Leukemia. Environmental Health Perspectives, 108(5), 441-445.
Owens, G. P., & Bennett, J. L. (2012). Trigger, pathogen, or bystander: the complex nexus linking Epstein– Barr virus and multiple sclerosis. Multiple Sclerosis Journal, 18(9), 1204-1208. Doi: 10.1177/1352458512448109
Papesch, M., & Watkins, R. (2001). Epstein-Barr virus infectious mononucleosis. Clinical Otolaryngology & Allied Sciences, 26(1), 3.
Pembrey, L., Waiblinger, D., Griffiths, P., Patel, M., Azad, R., & Wright, J. (2017). Cytomegalovirus, Epstein-Barr virus and varicella zoster virus infection in the first two years of life: a cohort study in Bradford, UK. BMC Infectious Diseases, 171-18. Doi: 10.1186/s12879-017-2319-7
Rasmussen, N. S., Nielsen, C. T., Houen, G., & Jacobsen, S. (2016). Humoral markers of active Epstein–Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus. Lupus, 25(14), 1567-1576. Doi: 10.1177/0961203316644334
Robertson, E. S. (2010). Epstein-Barr virus: Latency and transformation. Wymondham, Norfolk, UK: Caister Academic Press.
San-Juan, R., Comoli, P., Caillard, S., Moulin, B., Hirsch, H. H., & Meylan, P. (2014). Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clinical Microbiology & Infection, 20109-118. doi:10.1111/1469-0691.12534
Satoko, M., Shigeo, N., Kazuhito, Y., Hidemasa, M., Yoshitoyo, K., Tomohiro, K., & ... Seiko, I. (2015). Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. Leukemia & Lymphoma, 56(4), 1072-1078. doi:10.3109/10428194.2014.938326
Schlossberg, D. (1989). Infectious Mononucleosis. New York, NY: Springer US.
Simpson, J. S., Taylor, B. V., & Van der Mei, I. (2015). The role of epidemiology in MS research: Past successes, current challenges and future potential. Multiple Sclerosis Journal, 21(8), 969-977. Doi: 10.1177/1352458515574896
Strasburger, V. C. (2006). Adolescent Medicine: A Handbook for Primary Care. Philadelphia Presss.
Sulika A., Oldaka E., Krotena A., Lipskab A., Radziwon, P. (2014). Epstein–Barr virus effect on frequency of functionally distinct T cell subsets in children with infectious mononucleosis. Advances in Medical Sciences 59 (2014) 227–231.
Sumaya, C. V. (1977). Primary Epstein - Barr virus Infections in Children. Pediatrics, 59(1), 16.
Sumaya, C. V., & Ench, Y. (1985). Epstein - Barr virus Infectious Mononucleosis in Children I. Clinical and General Laboratory Findings. Pediatrics, 75(6), 1003.
Sumaya, C. V., & Ench, Y. (1985). Epstein - Barr virus Infectious Mononuclosis in Children II. Heterophil Antibody and Viral-Specific Responses. Pediatrics, 75(6), 1011.
Takada, K. (2001). Epstein - Barr virus and Human Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg.
Ting-bo, L., Zhi-hong, Z., Jie, P., Li-li, P., & Li-hong, C. (2017). Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis. Clinical & Investigative Medicine, 40(1), E1-E12.
Ting-bo, L., Zhi-hong, Z., Jie, P., Li-li, P., & Li-hong, C. (2017). Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis. Clinical & Investigative Medicine, 40(1), E1-E12.
Torii, Y., Kawada, J., Murata, T., Yoshiyama, H., Kimura, H., & Ito, Y. (2017). Epstein-Barr virus infection-induced inflammasome activation in human monocytes. Plos ONE, 12(4), 1-16. doi:10.1371/journal.pone.0175053
Umar, C. S. (2006). New developments in Epstein-Barr virus research. New York: Nova Science Publishers.
Vezina, H. E., Balfour Jr, H. H., Weller, D. R., Anderson, B. J., & Brundage, R. C. (2010). Valacyclovir Pharmacokinetics and Exploratory Pharmacodynamics in Young Adults with Epstein - Barr virus Infectious Mononucleosis. Journal of Clinical Pharmacology, 50(7), 734-742. Doi: 10.1177/0091270009351884
Visser, E., Milne, D., Collacott, I., McLernon, D., Counsell, C., & Vickers, M. (2014). The epidemiology of infectious mononucleosis in Northern Scotland: a decreasing incidence and winter peak. BMC Infectious Diseases, 14(1), 1-20. Doi: 10.1186/1471-2334-14-151
William, A. (2015). Medical medium: Secrets behind chronic and mystery illness and how to finally heal.
Scheld, W. M., In Whitley, R. J., & In Marra, C. M. (2014). Infections of the central nervous system.
